Background: Myoclonic movement is a common problem during induction of anesthesia with etomidate. We investigated the influences of pretreatment with remifentanil on etomidate induced myoclonus.
INTRODUCTION
Eomidate is a short-acting GABA (γ-aminobutyric acid) receptor-stimulating hypnotic agent causing minimal histamine release and a very stable hemodynamic profile [1] [2] [3] , however up to 80% of patients who are not premedication experience myoclonus that is a serious problem in patients with open globe injury or in non-fasting condition or limited cardiovascular reserve [3, 4] .
Previous researches have presented that a pretreatment with fentanyl reduces myoclonic movement and pain during the induction of anesthesia with etomidate. But alfentanil and buphrenorphine do not have any better efficiency in preventing myoclonus [1, 3] . Fentanyl stimulates μ-opioid receptor on GABA-nergic neurons in basal ganglia, which is known to decrease myoclonus [1, 5, 6] . These agents are suitable for long surgical procedure [4, 5] .
Remifentanil, as a μ-opioid receptor agonist, exhibits similar potency to fentanyl and it has a rapid onset of analgesic action (1 min) and a fast offset of action (3−10 min), and does not release histamine [7] [8] [9] . Furthermore, it produces fewer cardiovascular changes if small doses are used [7] . Considering the strengths, remifentanil is effectively used as a part of propofol-based total intravenous anesthesia or in combination with volatile anesthetics without prolonged recovery from anesthesia. 65.9 ± 10.5
All values except sex are mean ± SD. There are no statistical differences among the three Groups. Group NS: received normal saline 2 ml, group R0.5: pretreated with remifentanil 0.5 μg/kg, Group R1.0: pretreated with remifentanil 1.0 μg/kg before etomidate induction.
The purpose of this study was to know the reducing effect of remifentanil on myoclonus, and to compare the changes of mean arterial pressure (MAP), heart rate (HR) and bispectral index (BIS) during induction of anesthesia with etomidate.
MATERIALS AND METHODS
After obtaining approval by our Institutional Review Board and informed written consents from all participating patients, a prospective, randomized, double-blind study was performed.
Ninety American Society of Anesthesiologists physical status I patients scheduled for elective plastic surgery were selected as subjects (Table 1) . Patients with neurologic, cardiopulmonary or endocrine disease, those with known drug hypersensitivity, and those who were anticipating difficult intubation were excluded. Remifentanil to be used for this experiment was prepared after diluting with normal saline to 20 μg/ml outside the operating room by an anesthesiologist not involved in induction of anesthesia. In the operating room, electrocardiogram, pulse oximeter and noninvasive arterial blood pressure were monitored.
A standard BIS monitor strip (BIS A-2000, Aspect medical systems Inc., USA) was placed on the patients' forehead.
Intravenous (IV) glycopyrrolate 0.2 mg was given to each patient as a premedicant after confirming the IV route in dorsum hand with 18-gauge cannula.
Subsequently preoxygenation was performed with 100% O2 using face mask. After patient's vital signs were virtually unchanged, we recorded their MAP, HR, BIS data as a baseline values.
The patients were randomly allocated to three groups. Group NS received normal saline 2 ml, group R0.5 received re- 
RESULTS
There were no significant differences among the groups in age, weight, height and sex ( Table 1) . The incidence and duration of etomidate induced myoclonus were decreased significantly in both remifentanil groups than in normal saline group (Table 2) .
Though the onset of myoclonus did not vary among the three groups, the intensity of myoclonus significantly decreased in remifentanil groups (P ＜ 0.05) ( Table 2 ). In both of the remifentanil groups developed only grade 2 myoclonus, whereas 66.7% of group NS developed grade 3 or 4 myoclonus (Fig. 1 ).
In addition, the remifentanil groups indicated decreased MAP, when measured 1 min after etomidate induction (P ＜ 0.05) (Fig. 2) . Heart rates of both remifentanil groups decreased when measured not only 1 min after receiving remifentanil but also 1 min after induction with etomidate (P ＜ 0.05) (Fig. 3 ).
There were no cases of hypotension or bradycardia.
BIS was not different significantly among the three groups at all time points (Fig. 4) . The dose dependent effects of remifentanil 0.5 μg/kg and 1.0 μg/kg were not significantly noticed at all measurements.
DISCUSSION
Previous studies reported that remifentanil 1.0 μg/kg reduces the myoclonus incidence after etomidate 0.3 mg/kg injection [4] .
In general, the minimal bolus dose of remifentanil is 0.5 μg/kg, minutes [11] . In these reasons, the present study administered remifentanil at the time of 1 minute prior to induction with etomidate and we used two bolus doses of remifentanil 0.5 μg/kg and 1.0 μg/kg, but dose-dependent differences of remifentanil on reducing myoclonus were not noticeable.
There are some factors known to affect the occurrences of myoclonus, such as age, gender of a patient and dosages of the etomidate [4, 12] . In male, the incidence is 50−87.5%, however 50% in female, 11% in patients older than 60 years [4, 6] . Reddy et al. [13] investigated the excitatory movement including myoclonus, tremor and dystonic posture, occurred in 86.6% of patients receiving etomidate (mean age 66.1 yr) and 100% in children.
Moreover, the development of myoclonus is dose dependently different. The recommended induction dose of etomidate is usually 0.3−0.4 mg/kg, and for Korean women is approximately 0.2 mg/kg [12, 14] . The relatively higher doses of etomidate and younger ages of the subjects (average age of thirties) might have possibly affected our results, so the incidences and intensities of myoclonus were appeared somewhat higher.
The neurologic mechanism of myoclonus is unclear but one of the most possibilities is a disinhibition phenomenon of subcortical structure. That is etomidate depresses cortical activity before it depresses subcortical activity [6, 13] , thus depresses the inhibitory neural circuits prior to excitatory circuits and not caused by an epileptic focus [3, 6, 12] . The basis of this theory is that the excitatory phenomenon of myoclonus is caused by disequilibrium of the drug at the various target sites in the central nervous system. Differences in local cerebral blood flow or affinity might produce a temporary disequilibrium of effect, resulting in more rapid depression of cortical inhibition [6, 12] .
In addition, high concentration of etomidate interacts with GABAA receptors of central nervous reticular activating system.
With interruption of GABA neurons, pathways associated with skeletal muscle control can become more sensitive, allowing spontaneous nerve transmissions. These events can ultimately lead to myoclonic muscle contraction [5, 6] . For these ethical reasons, myoclonus can be prevented when premedication with benzodiazepines, fentanyl or others known to inhibit subcortical neuronal activity [3, 6] . Pretreatment with opioids reduced myoclonus and pain during induction of anesthesia with etomidate.
Pretreatment with fentanyl (100, 250, 500 μg) reduced the incidence of myoclonus (33%, 13%, 0%) but increased the incidence of apnea (87%, 87%, 100%) during induction [1, 4] . Hence it is reported that one of the important mechanism of cerebral protection is to inhibit the release of glutamate [15] .
Pretreatment with NMDA receptor antagonists such as magnesium sulfate (Mg) can effectively prevent etomidate induced myoclonus but not in case with ketamine [3] . Mg and ketamine may attenuate withdrawal movements or pain caused by various chemical mediators either in vascular endothelium or in the brain and the dorsal horn of the spinal cord [3, 16] . NMDA receptor agonist such as remifentanil induces the Ca ＋＋ influx, and result in production of nitric oxide (NO). This NO has an important role in development of postoperative pain and opiate tolerance [16] . Thus, the interaction of remifentanil and etomidate on NMDA receptors would need more investigations.
As for remifentanil, it produces minimal effects on the cardiovascular system with an expected mild bradycardia and 15− 20% decreases in arterial pressure. However, that could be mostly prevented through premedication with glycopyrrolate [7, 8] .
Meanwhile, etomidate decreases peripheral vascular resistance which is responsible for a slight decline in arterial blood pressure. Myocardial contractility and cardiac output remain unchanged [17] . We found that etomidate did not affect the MAP and HR during induction. Remifentanil 0.5 μg/kg and 1.0 μg/kg significantly decreased HR only before induction.
After etomidate administration, both HR and MAP were decreased significantly (Fig 2, 3) . Previous researches reported that remifentanil 1 μg/kg bolus followed by an infusion 0.5 μg/kg/min during anesthetic induction attenuate the hemodynamic response to laryngoscopy and tracheal intubation [18, 19] . We thought that bolus doses of remifentanil 0.5 and 1.0 μg/kg before the induction did not effectively attenuate the hemodynamic responses to intubation, because of its very short duration of action and short elimination time. (Fig 2, 3) .
BIS has been used as an indicator of measuring hypnotic effect of anesthetics and sedatives [20] [21] [22] . A BIS value of 50 was appropriate during tracheal intubation following etomidate induction. Myoclonus did not cause epileptic paroxysms or ictal spiking likely to alter BIS [21] . A BIS is derived from the EEG and reflects cortical activity, thus BIS cannot be considered a true reflection of the depth of anesthesia [22, 23] . Our study demonstrated that remifentanil did not affect the changes of BIS. We assumed that it was caused by sudden decreased BIS after administration of hypnotic dose of etomidate could not reflect the effect of remifentanil (Fig. 4) . In opioids, almost 5 times the analgesic concentrations would be required for the appearance of a noticeable EEG depression and analgesic concentrations of opioids produce minimal or no EEG alteration on cerebral cortex. If BIS suddenly increases in response to a noxious stimulus, this could be a cortical arousal reaction reflecting a deficit in the analgesic component [22] .
Our study demonstrated the BIS did not reflect the painful stimulus such as intubation, because the pain is subcortical activity not cortical component.
In conclusion, a bolus injection of remifentanil 1 min before induction of anesthesia with etomidate significantly decreased the incidence, duration and intensity of myoclonus without development of hypotension and bradycardia. In addition, a dose dependent effect of remifentanil 0.5 μg/kg and 1.0 μg/kg were not noticed. We expect that our results will be helpful during induction with etomidate and remifentanil in patients with poor cardiac reserve.
